Clinical trial
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer…
NCT00316186 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00316186 |
|---|---|
| Title | First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin |
| Official title | An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Small Cell |
| Intervention type | Drug |
| Interventions | topotecan, carboplatin |
| Enrollment | 33 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Apr 20, 2006 |
| Last update posted | May 7, 2015 |
| Countries | Poland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: